Dr. Reddy’s Laboratories has launched Olanzapine tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg), a bioequivalent generic version of ZYPREXA tablets in the US market on April 23, 2012 following the approval by the United States Food & Drug Administration (USFDA) of the company's ANDA for Olanzapine tablets.
Dr. Reddy’s Olanzapine tablets in 20 mg had been awarded a 180-day period of marketing exclusivity in the US on October 26, 2011 which was commercialized through a commercial, manufacture and supply agreement with Teva Pharmaceutical Industries.
The ZYPREXA tablets brand and generic had combined US sales of approximately $3.28 billion for the most recent twelve months ending January 2012 according to IMS Health.
Dr. Reddy’s Olanzapine tablets in 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg strengths are available in 30 and 500 count bottles.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: